Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 91 clinical trials
Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer

In this clinical study, the investigators evaluate the efficacy and safety of S-588410 in patients who underwent an adjuvant chemotherapy after the complete resection of non-small-cell lung cancer.

adjuvant chemotherapy
cancer chemotherapy
lung carcinoma
  • 21 Jan, 2021
  • 1 location
Safety Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

PDC-LUNG-101 trial is an open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer.

  • 30 Apr, 2021
  • 16 locations
Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related HLA-Haploidentical Donors

The purpose of this study is to determine if engraftment can be achieved safely in patients with high-risk hematologic malignancies who undergo non-myeloablative transplant with peripheral stem cells from Human Leukocyte Antigen (HLA) haploidentical donors with pre and post-transplant cyclophosphamide as immunosuppression.

cell transplantation
graft versus host disease
  • 23 Aug, 2021
  • 1 location
Haploidentical Donor vs mMUD in Hematological Malignancies

The goal of this trial is to compare the outcome after partially matched (single mismatch) unrelated donor transplantation with haploidentical transplantation in a randomized controlled setting.

minimal residual disease
neoadjuvant therapy
carbon monoxide
cell transplantation
residual tumor
  • 03 Sep, 2021
  • 11 locations
NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

The main purpose of this trial is to investigate the safety and tolerability of NY-ESO-1TCR Affinity Enhancing Specific T cell Therapyin the first-line treatment failed advanced bone and soft tissue sarcoma. The secondary purpose of this trial is to investigate the efficacy of NY-ESO-1TCR Affinity Enhancing Specific T cell Therapyin …

  • 27 Jan, 2021
  • 1 location
E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Background Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have a HPV protein called E7 inside of their cells. In this new therapy, researchers take a person s blood, remove certain white blood cells, and insert genes that make them to target cancer …

white blood cells
hepatitis b antigen
platelet count
  • 12 Sep, 2021
  • 1 location
Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer

Background Men who continue to have an elevated or rising prostate specific antigen (PSA) level after their primary prostate cancer treatment are at increased risk for their cancer to progress. The time it takes to progress is highly variable. One way to predict this progression is based on the change …

prostate specific antigen
definitive treatment
platelet count
cancer treatment
  • 12 Sep, 2021
  • 1 location
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Background In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient s immune system destroys the donor s cells. Or donor immune cells attack the recipient s tissues, called graft-versus-host disease (GVHD). This is less likely when the recipient …

bone lesion
chromosome abnormality
acute leukemia
white blood cells
hematologic malignancy
  • 20 Sep, 2021
  • 2 locations
Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients

The purpose of this study is to evaluate the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients.

  • 25 Apr, 2021
  • 1 location
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

Background GATA2 deficiency is a disease caused by mutations in the GATA2 gene. It can cause different types of leukemia and other diseases. Researchers want to see if a stem cell transplant can be used to treat this condition. A stem cell transplant will give stem cells from a matching …

conjugated bilirubin
total body irradiation
mycophenolate mofetil
allogeneic hematopoietic stem cell transplant
  • 12 Sep, 2021
  • 1 location